21st Austria weekly - Croma-Pharma, AT&S, SBO (01/06/2023)

Croma-Pharma: Croma-Pharma, an Austrian based global player and challenger in the minimally invasive aesthetics market, announces that it will launch Pliaglis®, a topical local anaesthetic for superficial dermatological procedures, in its European core markets including Germany, the United Kingdom ("UK"), and Ireland. Further markets including Brazil will follow by the end of 2023. The anaesthetic cream complements Croma's range of aesthetic injectables, a key pillar of its comprehensive and innovative aesthetics portfolio. The launch is preceded by an exclusive licensing agreement for Pliaglis® with Canadian dermatology company Crescita Therapeutics Inc. ("Crescita"). The agreement grants Croma the exclusive rights to commercialize Pliaglis in nine countries including Germany, ...

Den vollständigen Artikel lesen ...